Announcements
Parlodel
The licence for Parlodel (bromocriptine, as mesilate) has been transferred
from Novartis Pharmaceuticals to Meda Pharmaceuticals. Medical information
is now available from Meda on 01748 828810.
Visudyne
The Committee for Medicinal Products for Human Use has reviewed post-marketing
data for Visudyne (verteporfin; Novartis) and has specified that its
indication for “the treatment of patients with age-related macular
degeneration with occult subfoveal choroidal neovascularisation with
evidence of recent or ongoing disease progression” be deleted
because the benefit–risk profile is no longer considered favourable. |
The
Pharmaceutical Journal